Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling-Reference-Cited by-同舟云学术

Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling

Published:2024-03-17 Issue:4 Volume:51 Page:319-333
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Schirru Miriam,Charef Hamza,Ismaili Khalil-Elmehdi,Fenneteau Frédérique,Zugaj Didier,Tremblay Pierre-Olivier,Nekka Fahima

Funder

FRQNT-Projet d’équipe

Syneos Health

Prompt

NSERC

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10928-024-09903-0.pdf

Reference53 articles.

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer Immunoediting: integrating immunity’s roles in Cancer suppression and Promotion. Science 331:1565–1570. https://doi.org/10.1126/science.1203486

2. Upadhaya S, Neftelinov ST, Hodge J, Campbell J (2022) Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov 21:482–483. https://doi.org/10.1038/d41573-022-00030-4

3. Chelliah V, Lazarou G, Bhatnagar S et al (2021) Quantitative systems Pharmacology Approaches for Immuno-Oncology: adding virtual patients to the Development paradigm. Clin Pharmacol Ther 109:605–618. https://doi.org/10.1002/cpt.1987

4. Prasad V, Mailankody S (2017) Research and development spending to bring a single Cancer drug to market and revenues after approval. JAMA Intern Med 177:1569. https://doi.org/10.1001/jamainternmed.2017.3601

5. Bradshaw EL, Spilker ME, Zang R et al (2019) Applications of quantitative systems Pharmacology in Model-Informed Drug Discovery: perspective on Impact and opportunities. CPT Pharmacometrics Syst Pharmacol 8:777–791. https://doi.org/10.1002/psp4.12463